{"success":true,"data":{"pressRelease":{"id":"164673","rtpr_id":"nPn6pzphra-20261008","ticker":"BBNX","exchange":"NASDAQ","all_tickers":["BBNX"],"title":"Beta Bionics (BBNX) Alert: Securities Class Action Filed, Investors with Losses Encouraged to Contact Hagens Berman Before November 3, 2026 Lead Plaintiff Deadline","author":"PR Newswire","published_at":"2026-10-08T15:37:00.023Z","article_body":"Beta Bionics (BBNX) Alert: Securities Class Action Filed, Investors with Losses Encouraged to Contact Hagens Berman Before November 3, 2026 Lead Plaintiff Deadline\nPR Newswire\n\nSAN FRANCISCO, Oct. 8, 2026\n\nSAN FRANCISCO, Oct. 8, 2026 /PRNewswire/ -- Beta Bionics, Inc. (NASDAQ:\nBBNX) faces a securities class action, which seeks to represent investors who\npurchased or otherwise acquired shares of the company's common stock between\nJuly 30, 2025 and February 24, 2026.\n\nThe lawsuit follows a series of surprise revelations about the FDA's concerns\nover company's automated insulin delivery system (\"iLet\"), each of which sent\nthe price of Beta Bionics shares sharply lower.\n\nNational shareholders rights firm Hagens Berman is investigating claims that\nBeta Bionics violated the federal securities laws and encourages Beta Bionics\ninvestors who suffered substantial losses to submit your losses now\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4792728-1&h=2788553411&u=https%3A%2F%2Fwww.hbsslaw.com%2Fcases%2Fbeta-bionics-inc-bbnx-securities-class-action&a=submit+your+losses+now)\n.\n\nClass Period: July 30, 2025 – Feb. 24, 2026\nLead Plaintiff Deadline: Nov. 3, 2026\nVisit: www.hbsslaw.com/bbnx\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4792728-1&h=616616062&u=https%3A%2F%2Fwww.hbsslaw.com%2Fbbnx&a=www.hbsslaw.com%2Fbbnx)\n\nDirect Contact Email: BBNX@hbsslaw.com (mailto:BBNX@hbsslaw.com)\nFirm Telephone: 844-916-0895\nBeta Bionics (BBNX) Securities Class Action:\n\nDuring the Class Period, the company and its management heavily promoted its\niLet medical device as demanding \"the least engagement from the user\" and\ndelivering \"the most automated adaptation of any\" automated insulin delivery\nsystem. Beta Bionics also assured investors that healthcare professionals \"are\nseeing good results from their patients and becoming more comfortable\nprescribing the iLet[.]\"\n\nOn October 28, 2025, Beta Bionics' management discussed their receipt of a\nForm 483 from the FDA after its inspection of Beta Bionics' iLet\nmanufacturing, they called the 483 \"primarily related to our customer\ncomplaint handling system,\" downplayed the inspection as \"not unusual in our\nindustry,\" and said \"[w]e're confident that our new complaint handling system\nand reporting system meets or exceeds the expectations laid out by the agency\nin their Form 483 observations.\"  CEO Sean Saint emphasized \"[t]he 483 itself\nhad nothing to do with the actual complaints being received[….] It had to do\nsolely with the definition the reports being filed as complaints, and that's\nall.\"\n\nThe complaint alleges these and other statements misled investors because,\nunknown to them, Beta Bionics concealed its receipt of thousands of iLet\nsafety complaints, including numerous life-threatening hypoglycemic events,\nand failed to investigate or report the events to the FDA as it was required\nto do.\n\nBy February 24, 2026, when the FDA published its January 28, 2026 WARNING\nLETTER to CEO Saint, investors learned the truth. The FDA, citing its\ninspection, was brutal:\n\n * \"Your firm failed to adequately analyze quality data, such as complaints, to\nidentify existing and potential causes of nonconforming product or other\nquality problems[;]\"\n * \"Your firm failed to implement corrective and preventative actions […] for\ncomplaints related to device malfunctions that led to serious adverse health\noutcomes[;]\" and\n * \"Significant violations include […] [f]ailure to report to the FDA\ninformation […] no later than 30 calendar days after the day that your firm\nreceived or otherwise became aware of information, from any source, that\nreasonably suggests that a device that it markets may have caused or\ncontributed to a death or serious injury[.]\"\n\"We're focused on whether Beta Bionics may have intentionally misled investors\nby placing revenues ahead of patient safety,\" said Reed Kathrein\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4792728-1&h=3894656736&u=https%3A%2F%2Fwww.hbsslaw.com%2Fattorneys%2Freed-kathrein&a=Reed+Kathrein)\n, the Hagens Berman partner leading the firm's investigation.\n\nIf you invested in Beta Bionics and have substantial losses, or have knowledge\nthat will assist the firm's investigation, submit your losses now\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4792728-1&h=2788553411&u=https%3A%2F%2Fwww.hbsslaw.com%2Fcases%2Fbeta-bionics-inc-bbnx-securities-class-action&a=submit+your+losses+now)\n »\n\nWhistleblowers: Persons with non-public information regarding Beta Bionics\nshould consider their options to help in the investigation or take advantage\nof the SEC Whistleblower program. Under the new program, whistleblowers who\nprovide original information may receive rewards totaling up to 30 percent of\nany successful recovery made by the SEC. For more information, call Reed\nKathrein at 844-916-0895 or email BBNX@hbsslaw.com (mailto:BBNX@hbsslaw.com)\n.\n\nAbout Hagens Berman\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4792728-1&h=1945226372&u=https%3A%2F%2Fwww.hbsslaw.com%2F&a=About+Hagens+Berman)\n\nHagens Berman is a global plaintiffs' rights complex litigation firm focusing\non corporate accountability. The firm is home to a robust practice and\nrepresents investors as well as whistleblowers, workers, consumers and others\nin cases achieving real results for those harmed by corporate negligence and\nother wrongdoings. Hagens Berman's team has secured more than $2.9 billion in\nthis area of law. More about the firm and its successes can be found\nat hbsslaw.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4792728-1&h=2521375165&u=https%3A%2F%2Fwww.hbsslaw.com%2F&a=hbsslaw.com)\n. Follow the firm for updates and news at @ClassActionLaw\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4792728-1&h=2899635891&u=https%3A%2F%2Fwww.twitter.com%2FClassActionLaw&a=%40ClassActionLaw)\n.\n\nAttorney Advertising. Prior results do not guarantee a similar outcome in any\nfuture case.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/beta-bionics-bbnx-alert-securities-class-action-filed-investors-with-losses-encouraged-to-contact-hagens-berman-before-november-3-2026-lead-plaintiff-deadline-302902611.html\n(https://www.prnewswire.com/news-releases/beta-bionics-bbnx-alert-securities-class-action-filed-investors-with-losses-encouraged-to-contact-hagens-berman-before-november-3-2026-lead-plaintiff-deadline-302902611.html)\n\nSOURCE Hagens Berman Sobol Shapiro LLP\n\n\n\nHagens Berman, Reed Kathrein, 715 Hearst Avenue, Suite 300, Berkeley, CA 94710, 844-916-0895, BBNX@hbsslaw.com\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1117217/Hagens-Berman-Sobol-Shapiro-LLP-Logo.jpg?id=OA2994888\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn6pzphra-20261008","title":"Beta Bionics (BBNX) Alert: Securities Class Action Filed, Investors with Losses Encouraged to Contact Hagens Berman Before November 3, 2026 Lead Plaintiff Deadline","author":"PR Newswire","ticker":"BBNX","created":"2026-10-08T15:37:00.023Z","tickers":["BBNX"],"exchange":"NASDAQ","article_body":"Beta Bionics (BBNX) Alert: Securities Class Action Filed, Investors with Losses Encouraged to Contact Hagens Berman Before November 3, 2026 Lead Plaintiff Deadline\nPR Newswire\n\nSAN FRANCISCO, Oct. 8, 2026\n\nSAN FRANCISCO, Oct. 8, 2026 /PRNewswire/ -- Beta Bionics, Inc. (NASDAQ:\nBBNX) faces a securities class action, which seeks to represent investors who\npurchased or otherwise acquired shares of the company's common stock between\nJuly 30, 2025 and February 24, 2026.\n\nThe lawsuit follows a series of surprise revelations about the FDA's concerns\nover company's automated insulin delivery system (\"iLet\"), each of which sent\nthe price of Beta Bionics shares sharply lower.\n\nNational shareholders rights firm Hagens Berman is investigating claims that\nBeta Bionics violated the federal securities laws and encourages Beta Bionics\ninvestors who suffered substantial losses to submit your losses now\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4792728-1&h=2788553411&u=https%3A%2F%2Fwww.hbsslaw.com%2Fcases%2Fbeta-bionics-inc-bbnx-securities-class-action&a=submit+your+losses+now)\n.\n\nClass Period: July 30, 2025 – Feb. 24, 2026\nLead Plaintiff Deadline: Nov. 3, 2026\nVisit: www.hbsslaw.com/bbnx\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4792728-1&h=616616062&u=https%3A%2F%2Fwww.hbsslaw.com%2Fbbnx&a=www.hbsslaw.com%2Fbbnx)\n\nDirect Contact Email: BBNX@hbsslaw.com (mailto:BBNX@hbsslaw.com)\nFirm Telephone: 844-916-0895\nBeta Bionics (BBNX) Securities Class Action:\n\nDuring the Class Period, the company and its management heavily promoted its\niLet medical device as demanding \"the least engagement from the user\" and\ndelivering \"the most automated adaptation of any\" automated insulin delivery\nsystem. Beta Bionics also assured investors that healthcare professionals \"are\nseeing good results from their patients and becoming more comfortable\nprescribing the iLet[.]\"\n\nOn October 28, 2025, Beta Bionics' management discussed their receipt of a\nForm 483 from the FDA after its inspection of Beta Bionics' iLet\nmanufacturing, they called the 483 \"primarily related to our customer\ncomplaint handling system,\" downplayed the inspection as \"not unusual in our\nindustry,\" and said \"[w]e're confident that our new complaint handling system\nand reporting system meets or exceeds the expectations laid out by the agency\nin their Form 483 observations.\"  CEO Sean Saint emphasized \"[t]he 483 itself\nhad nothing to do with the actual complaints being received[….] It had to do\nsolely with the definition the reports being filed as complaints, and that's\nall.\"\n\nThe complaint alleges these and other statements misled investors because,\nunknown to them, Beta Bionics concealed its receipt of thousands of iLet\nsafety complaints, including numerous life-threatening hypoglycemic events,\nand failed to investigate or report the events to the FDA as it was required\nto do.\n\nBy February 24, 2026, when the FDA published its January 28, 2026 WARNING\nLETTER to CEO Saint, investors learned the truth. The FDA, citing its\ninspection, was brutal:\n\n * \"Your firm failed to adequately analyze quality data, such as complaints, to\nidentify existing and potential causes of nonconforming product or other\nquality problems[;]\"\n * \"Your firm failed to implement corrective and preventative actions […] for\ncomplaints related to device malfunctions that led to serious adverse health\noutcomes[;]\" and\n * \"Significant violations include […] [f]ailure to report to the FDA\ninformation […] no later than 30 calendar days after the day that your firm\nreceived or otherwise became aware of information, from any source, that\nreasonably suggests that a device that it markets may have caused or\ncontributed to a death or serious injury[.]\"\n\"We're focused on whether Beta Bionics may have intentionally misled investors\nby placing revenues ahead of patient safety,\" said Reed Kathrein\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4792728-1&h=3894656736&u=https%3A%2F%2Fwww.hbsslaw.com%2Fattorneys%2Freed-kathrein&a=Reed+Kathrein)\n, the Hagens Berman partner leading the firm's investigation.\n\nIf you invested in Beta Bionics and have substantial losses, or have knowledge\nthat will assist the firm's investigation, submit your losses now\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4792728-1&h=2788553411&u=https%3A%2F%2Fwww.hbsslaw.com%2Fcases%2Fbeta-bionics-inc-bbnx-securities-class-action&a=submit+your+losses+now)\n »\n\nWhistleblowers: Persons with non-public information regarding Beta Bionics\nshould consider their options to help in the investigation or take advantage\nof the SEC Whistleblower program. Under the new program, whistleblowers who\nprovide original information may receive rewards totaling up to 30 percent of\nany successful recovery made by the SEC. For more information, call Reed\nKathrein at 844-916-0895 or email BBNX@hbsslaw.com (mailto:BBNX@hbsslaw.com)\n.\n\nAbout Hagens Berman\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4792728-1&h=1945226372&u=https%3A%2F%2Fwww.hbsslaw.com%2F&a=About+Hagens+Berman)\n\nHagens Berman is a global plaintiffs' rights complex litigation firm focusing\non corporate accountability. The firm is home to a robust practice and\nrepresents investors as well as whistleblowers, workers, consumers and others\nin cases achieving real results for those harmed by corporate negligence and\nother wrongdoings. Hagens Berman's team has secured more than $2.9 billion in\nthis area of law. More about the firm and its successes can be found\nat hbsslaw.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4792728-1&h=2521375165&u=https%3A%2F%2Fwww.hbsslaw.com%2F&a=hbsslaw.com)\n. Follow the firm for updates and news at @ClassActionLaw\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4792728-1&h=2899635891&u=https%3A%2F%2Fwww.twitter.com%2FClassActionLaw&a=%40ClassActionLaw)\n.\n\nAttorney Advertising. Prior results do not guarantee a similar outcome in any\nfuture case.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/beta-bionics-bbnx-alert-securities-class-action-filed-investors-with-losses-encouraged-to-contact-hagens-berman-before-november-3-2026-lead-plaintiff-deadline-302902611.html\n(https://www.prnewswire.com/news-releases/beta-bionics-bbnx-alert-securities-class-action-filed-investors-with-losses-encouraged-to-contact-hagens-berman-before-november-3-2026-lead-plaintiff-deadline-302902611.html)\n\nSOURCE Hagens Berman Sobol Shapiro LLP\n\n\n\nHagens Berman, Reed Kathrein, 715 Hearst Avenue, Suite 300, Berkeley, CA 94710, 844-916-0895, BBNX@hbsslaw.com\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1117217/Hagens-Berman-Sobol-Shapiro-LLP-Logo.jpg?id=OA2994888\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-08T15:37:00.073609547Z","server_sent_at_ms":1791473820073},"received_at":"2026-10-08T15:37:00.124Z","source_url":"https://www.prnewswire.com/news-releases/beta-bionics-bbnx-alert-securities-class-action-filed-investors-with-losses-encouraged-to-contact-hagens-berman-before-november-3-2026-lead-plaintiff-deadline-302902611.html"},"analysis":{"id":"153083","press_release_id":"164673","analysis_json":{"redFlags":["FDA warning letter cited failure to report device-caused deaths or serious injuries within 30 days","alleged concealment of thousands of iLet safety complaints including life-threatening hypoglycemic events","pending securities class action with Nov. 3, 2026 lead plaintiff deadline"],"eventType":"legal_litigation","narrative":"Hagens Berman issued a shareholder-solicitation release announcing it is investigating claims in a securities class action against Beta Bionics (BBNX), covering the class period of July 30, 2025 through Feb. 24, 2026.\n\nThe complaint alleges Beta Bionics concealed thousands of iLet safety complaints and failed to report serious adverse events to the FDA, which issued a January 28, 2026 warning letter disclosed on Feb. 24, 2026.\n\nThe lead plaintiff deadline is Nov. 3, 2026; this is law-firm marketing rather than new issuer disclosure, though it re-surfaces material FDA quality-system allegations against the iLet.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress; note underlying FDA warning-letter risk separately if not already flagged."},"keyFigures":{"customDimensions":{"class_period_end":"Feb. 24, 2026","class_period_start":"July 30, 2025","hbsslaw_recoveries":"$2.9 billion","lead_plaintiff_deadline":"Nov. 3, 2026","whistleblower_reward_max":"30 percent of successful SEC recovery"}},"quotedText":"We're focused on whether Beta Bionics may have intentionally misled investors by placing revenues ahead of patient safety","namedEntities":{"people":[{"name":"Sean Saint","role":"CEO of Beta Bionics"},{"name":"Reed Kathrein","role":"Hagens Berman partner leading the investigation"}],"products":["iLet"],"companies":[{"name":"Beta Bionics, Inc.","ticker":"BBNX","relationship":"target of securities class action"},{"name":"Hagens Berman Sobol Shapiro LLP","relationship":"plaintiff law firm / release author"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"}],"dollarAmounts":[{"amount":"$2.9 billion","context":"total recoveries historically secured by Hagens Berman in corporate accountability cases"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff-law-firm solicitation issued by Hagens Berman under its own name, soliciting investors ahead of a lead plaintiff deadline. No certified class or settlement disclosed; the underlying FDA warning letter and litigation are pre-existing facts."},"tickerRelevance":{"others":[],"primary":"BBNX"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingIssueSeverity":"FDA warning letter on medical device safety"}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Hagens Berman issued a shareholder-solicitation release announcing it is investigating claims in a securities class action against Beta Bionics (BBNX), covering the class period of July 30, 2025 through Feb. 24, 2026.\n\nThe complaint alleges Beta Bionics concealed thousands of iLet safety complaints and failed to report serious adverse events to the FDA, which issued a January 28, 2026 warning letter disclosed on Feb. 24, 2026.\n\nThe lead plaintiff deadline is Nov. 3, 2026; this is law-firm marketing rather than new issuer disclosure, though it re-surfaces material FDA quality-system allegations against the iLet.","key_figures":{"customDimensions":{"class_period_end":"Feb. 24, 2026","class_period_start":"July 30, 2025","hbsslaw_recoveries":"$2.9 billion","lead_plaintiff_deadline":"Nov. 3, 2026","whistleblower_reward_max":"30 percent of successful SEC recovery"}},"named_entities":{"people":[{"name":"Sean Saint","role":"CEO of Beta Bionics"},{"name":"Reed Kathrein","role":"Hagens Berman partner leading the investigation"}],"products":["iLet"],"companies":[{"name":"Beta Bionics, Inc.","ticker":"BBNX","relationship":"target of securities class action"},{"name":"Hagens Berman Sobol Shapiro LLP","relationship":"plaintiff law firm / release author"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"}],"dollarAmounts":[{"amount":"$2.9 billion","context":"total recoveries historically secured by Hagens Berman in corporate accountability cases"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-08T15:37:06.493Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingIssueSeverity":"FDA warning letter on medical device safety"}},"durationMs":6361,"modelName":"glm-5.3-flashx"}}